Advertisement
Advertisement

INSM

INSM logo

Insmed, Inc.

105.36
USD
Sponsored
-1.55
-1.45%
Jun 01, 15:10 UTC -4
Open

INSM Earnings Reports

Positive Surprise Ratio

INSM beat 16 of 42 last estimates.

38%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$398.97M
/
-$0.82
Implied change from Q1 26 (Revenue/ EPS)
+30.40%
/
+7.89%
Implied change from Q2 25 (Revenue/ EPS)
+271.43%
/
-51.76%

Insmed, Inc. earnings per share and revenue

On May 07, 2026, INSM reported earnings of -0.76 USD per share (EPS) for Q1 26, beating the estimate of -0.97 USD, resulting in a 22.34% surprise. Revenue reached 305.96 million, compared to an expected 309.36 million, with a -1.10% difference. The market reacted with a -23.41% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.82 USD, with revenue projected to reach 398.97 million USD, implying an increase of 7.89% EPS, and increase of 30.40% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
logo
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
logo
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
logo
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
logo
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-
Actual
-$4.76
Surprise
-
logo
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
logo
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
logo
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
For Q1 2026, Insmed, Inc. reported EPS of -$0.76, beating estimates by 22.34%, and revenue of $305.96M, -1.1% below expectations.
The stock price moved down -23.41%, changed from $137.09 before the earnings release to $105.00 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 10 analysts, Insmed, Inc. is expected to report EPS of -$0.82 and revenue of $398.97M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement